Kymera Therapeutics KYMR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$315M-30.8% | -$311.35M-39.1% | -$295.12M-76.2% | -$275.43M-74.5% | -$240.88M-55.8% | ||
| $8.29M+4.1% | $8.31M+12.7% | $8.27M+31.7% | $8.11M+56.3% | $7.96M+91.9% | ||
| $61.68M+7.7% | $59.9M+8.9% | $59.25M+13.7% | $58.35M+19.4% | $57.28M+25.3% | ||
| -$242.58M-3.6% | -$232.89M-19.7% | -$227.93M-71.7% | -$251.01M-120% | -$234.06M-120% | ||
| $1.42M-76.8% | $1.45M-88.9% | $2.28M-90.4% | $2.1M-93.4% | $6.09M-83.9% | ||
| -$712.52M— | -$521.06M— | —— | —— | —— | ||
| $1.01B+295% | $990.71M+62.7% | $288.26M-52.6% | $499.67M+39.9% | $255.35M-28.5% | ||
| $54.13M+1,620% | $236.76M+2,205% | $2.24M-92.5% | $268.18M+1,657% | -$3.56M-108% | ||
| -$244M-1.7% | -$234.34M-13.0% | -$230.21M-55.3% | -$252.92M-83.4% | -$239.96M-76.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
